Entrada Therapeutics, Inc. (TRDA) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.
The consensus price target is $18.00 (low: $13.00, high: $21.00), representing an upside of 28.3% from the current price $14.03.
Analysts estimate Earnings Per Share (EPS) of $1.05 and revenue of $0.19B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $1.76 vs est $1.05 (beat +67.1%). 2025: actual $-3.47 vs est $-3.61 (beat +3.8%). Analyst accuracy: 78%.
TRDA Stock — 12-Month Price Forecast
$18.00
▲ +28.30% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Entrada Therapeutics, Inc., the average price target is $18.00, with a high forecast of $21.00, and a low forecast of $13.00.
The average price target represents a +28.30% change from the last price of $14.03.
Highest Price Target
$21.00
Average Price Target
$18.00
Lowest Price Target
$13.00
TRDA Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Entrada Therapeutics, Inc. in the past 3 months
EPS Estimates — TRDA
78%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $1.76
vs Est $1.05
▲ 40.2% off
2025
Actual –$3.47
vs Est –$3.61
▲ 3.9% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — TRDA
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.211B
vs Est $0.187B
▲ 11.5% off
2025
Actual $0.025B
vs Est $0.030B
▼ 19.8% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
